Tarsus is pursuing a milestone-driven acquisition of IRX-101, expanding its late-stage eye-care pipeline. The upfront $75 million (cash and stock) and potential $490 million in milestones could deliver meaningful optionality if IRX-101 reaches regulatory and commercial milestones, with Phase 3 enrollment slated for H1 2027 and results expected in 2028. The deal sparked a stock drop, reflecting near-term dilution and execution risk.
- Tarsus Pharmaceuticals had a quarterly loss of $1.01 per share, beating estimates by 12.17%. - Company's revenues for the quarter ended March 2024 were $27.61 million, exceeding estimates by 53.97%. - Tarsus Pharmaceuticals shares have increased by about 87.8% since the beginning of the year. Price Impact Rating: Bullish Impact Horizon Rating: Short-term Type: Earnings
